InSights Videos

Contract Manufacturing in the Pharmaceutical Industry: Recipharm

Contract Manufacturing in the Pharmaceutical Industry: Recipharm

In this exclusive interview, Fintan Walton, CEO of PharmaVentures, speaks with Marc Funk, the new CEO of Recipharm. Recipharm is a leading Swedish CDMO, founded in 1995, which has expanded to over 30 sites across 10 countries which are mainly in Europe, but also in...

Contract Manufacturing in the Pharmaceutical Industry: Recipharm

The Divestment Challenge Interview

In this special edition of PharmaVentures Insights, we explore the challenges faced by pharmaceutical companies during the manufacturing divestment process, and how to accelerate the divestment process to achieve a successful outcome. Paul Larsmon spoke with leading...

Contract Manufacturing in the Pharmaceutical Industry: Recipharm

Doing deals in the healthcare sector during the Covid-19 pandemic.

The Chief Executive of PharmaVentures, a leading global corporate advisory firm in healthcare licensing, M&A and fundraising discusses how the current pandemic of 2020 will define the winners and losers in biopharmaceuticals. https://youtu.be/o81Th7McuHA

Contract Manufacturing in the Pharmaceutical Industry: Recipharm

Why you should make South Korea a deal making target

Over the past couple of years, we have seen huge growth in the pharma and biotech industries in Asia, and especially in Korea. Historically, the Korean pharmaceutical industry was built on manufacturing and generics capabilities, however, in the past few decades many...

Featured Videos

Manufacturing Operations Divestment Expertise

Visit our YouTube channel for more videos

Blog Articles

Biotech Bounces Back

On the 31st July of this year the Financial Times front page headline to its Companies and Markets...

Our Termsheet

White Papers

Non-Small Cell Lung Cancer (NSCLC)

NSCLC is one of the most active areas of innovation in Oncology, and recent consensus estimates indicate that an additional $20BN of sales could be added in the indication over the next few years.

Our News